FUOM: A Protein Potential Drug Target Or Biomarker for Diseases

FUOM: A Protein Potential Drug Target Or Biomarker for Diseases

FUOM (FUCM-HUMAN) is a protein that is expressed in human tissues and has been identified as a potential drug target or biomarker for several diseases. FUOM is a key regulator of the cell cycle and has been shown to play a role in a variety of cellular processes, including cell growth, apoptosis, and angiogenesis.

The FUOM protein is composed of 19 different amino acid residues and has a calculated molecular weight of 21 kDa. FUOM is expressed in a variety of human tissues, including the brain, heart, liver, and pancreas. It is also expressed in the testes and has been shown to be highly expressed in cancer cells.

One of the key functions of FUOM is its role in regulating the cell cycle. FUOM is a component of the mitotic spindle, which is a structure that pulls the chromosomes apart during cell division. FUOM helps to keep the spindle stable and ensures that the chromosomes are properly aligned before cell division occurs.

In addition to its role in cell division, FUOM is also involved in apoptosis, which is the process by which cells die when they have reached the end of their life. FUOM has been shown to play a role in regulating apoptosis in various cell types and has been shown to be involved in the process of neurodegeneration.

FUOM has also been shown to be involved in angiogenesis, which is the process by which new blood vessels form in the body. FUOM has been shown to play a role in the regulation of angiogenesis in various tissues and has been shown to be involved in the formation of new blood vessels in the brain.

Due to its involvement in so many cellular processes, FUOM has been identified as a potential drug target or biomarker for a variety of diseases. For example, FUOM has been shown to be involved in the development and progression of cancer, and has been identified as a potential therapeutic target for cancer. In addition, FUOM has also been shown to be involved in the regulation of neurodegeneration and has been identified as a potential therapeutic target for neurodegenerative diseases.

FUOM has also been shown to be involved in the regulation of inflammation, and has been identified as a potential therapeutic target for a variety of inflammatory diseases. For example, FUOM has been shown to play a role in the regulation of the immune response and has been identified as a potential therapeutic target for rheumatoid arthritis.

In conclusion, FUOM is a protein that is expressed in human tissues and has been shown to play a role in a variety of cellular processes. FUOM has been identified as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and inflammatory diseases. Further research is needed to fully understand the role of FUOM in these diseases and to develop effective therapies.

Protein Name: Fucose Mutarotase

Functions: Involved in the interconversion between alpha- and beta-L-fucoses. L-Fucose (6-deoxy-L-galactose) exists as alpha-L-fucose (29.5%) and beta-L-fucose (70.5%), the beta-form is metabolized through the salvage pathway. GDP-L-fucose formed either by the de novo or salvage pathways is transported into the endoplasmic reticulum, where it serves as a substrate for N- and O-glycosylations by fucosyltransferases. Fucosylated structures expressed on cell surfaces or secreted in biological fluids are believed to play a critical role in cell-cell adhesion and recognition processes

The "FUOM Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FUOM comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

FURIN | FUS | FUT1 | FUT10 | FUT11 | FUT2 | FUT3 | FUT4 | FUT5 | FUT6 | FUT7 | FUT8 | FUT8-AS1 | FUT9 | FUZ | FXN | FXR1 | FXR2 | FXYD1 | FXYD2 | FXYD3 | FXYD4 | FXYD5 | FXYD6 | FXYD6-FXYD2 | FXYD7 | FYB1 | FYB2 | FYCO1 | FYN | FYTTD1 | FZD1 | FZD10 | FZD10-AS1 | FZD2 | FZD3 | FZD4 | FZD4-DT | FZD5 | FZD6 | FZD7 | FZD8 | FZD9 | FZR1 | G protein-Coupled Inwardly-Rectifying Potassium Channel (GIRK) | G Protein-Coupled Receptor Kinases (GRKs) | G0S2 | G2E3 | G2E3-AS1 | G3BP1 | G3BP2 | G6PC1 | G6PC2 | G6PC3 | G6PD | GA-binding protein | GAA | GAB1 | GAB2 | GAB3 | GAB4 | GABA(A) receptor | GABARAP | GABARAPL1 | GABARAPL2 | GABARAPL3 | GABBR1 | GABBR2 | GABPA | GABPAP | GABPB1 | GABPB1-AS1 | GABPB1-IT1 | GABPB2 | GABRA1 | GABRA2 | GABRA3 | GABRA4 | GABRA5 | GABRA6 | GABRB1 | GABRB2 | GABRB3 | GABRD | GABRE | GABRG1 | GABRG2 | GABRG3 | GABRG3-AS1 | GABRP | GABRQ | GABRR1 | GABRR2 | GABRR3 | GACAT1 | GACAT2 | GACAT3 | GAD1 | GAD2 | GADD45A